🇺🇸 FDA

Company profile · Sponsor

VYNE

VYNE Therapeutics

VYNE · NYSE pharma BRIDGEWATER, NJ, USA
Pipeline
24
Drugs
0
Patents
7

Quick answer

VYNE (VYNE) is a pharma company. headquartered in BRIDGEWATER, NJ, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 7 patents to this profile..

Company facts

Ticker VYNE
Exchange NYSE
Company type pharma
Headquarters BRIDGEWATER, NJ, USA
SEC CIK 0001566044

Pipeline (24)

Search pipeline →

  1. 5 mg Serlopitant Tablets

    VYNE

    Pruritus

    phase 3 small molecule terminated

    3 trials

  2. 5mg Serlopitant Tablets

    VYNE

    Pruritus

    phase 3 small molecule completed

    2 trials

  3. FMX-101, 4% minocycline foam

    VYNE

    Acne Vulgaris

    phase 3 small molecule completed

    2 trials

  4. FMX101

    VYNE

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial

  5. FMX103 1.5%

    VYNE

    Papulopustular Rosacea

    phase 3 small molecule completed

    1 trial

  6. FMX103 minocycline foam 1.5%

    VYNE

    Facial Papulopustular Rosacea

    phase 3 small molecule completed

    2 trials

  7. 5 mg Serlopitant Tablets

    VYNE

    Refractory Chronic Cough

    phase 2 small molecule completed

    1 trial

  8. ARK-E021 5%

    VYNE

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial

  9. Comparator: MK0594 5 mg/day

    VYNE

    Alcohol Dependence

    phase 2 small molecule terminated

    1 trial

  10. FCD105

    VYNE

    Acne Vulgaris

    phase 2 other completed

    1 trial

  11. FDX104 (4% Doxycycline)

    VYNE

    Rash Due to Epidermal Growth Factor Receptor Inhibitors

    phase 2 small molecule completed

    1 trial

  12. FMX-103 1.5%

    VYNE

    Rosacea

    phase 2 small molecule completed

    1 trial

  13. FMX114

    VYNE

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  14. MK0594

    VYNE

    Urinary Incontinence

    phase 2 small molecule completed

    1 trial

  15. Permethrin Foam 4%

    VYNE

    Scabies

    phase 2 small molecule completed

    1 trial

  16. Serlopitant

    VYNE

    Pruritus

    phase 2 small molecule terminated

    1 trial

  17. Serlopitant High Dose

    VYNE

    Pruritus

    phase 2 small molecule completed

    1 trial

  18. Serlopitant Tablet

    VYNE

    Epidermolysis Bullosa

    phase 2 small molecule completed

    1 trial

  19. Topical Minocycline Foam FXFM244

    VYNE

    Rosacea

    phase 2 small molecule terminated

    1 trial

  20. Topical Minocycline Foam FXFM244

    VYNE

    Impetigo

    phase 2 small molecule completed

    1 trial

  21. Topical Minocycline Foam FXFM244

    VYNE

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial

  22. VPD-737

    VYNE

    Chronic Pruritus

    phase 2 small molecule completed

    1 trial

  23. VPD-737

    VYNE

    Epidermolysis Bullosa

    phase 2 small molecule completed

    1 trial

  24. VYN201 Gel

    VYNE

    Non-segmental Vitiligo

    phase 2 small molecule terminated

    1 trial

Patents (7)

Search patents →

  1. US 11433025

    Oil foamable carriers and formulations

    Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11219631

    Foamable compositions, breakable foams and their uses

    Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11103454

    Wax foamable vehicle and pharmaceutical compositions thereof

    Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11033491

    Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof

    Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11026920

    Use of NK-1 receptor antagonist serlopitant in pruritus

    Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10967063

    Surfactant-free, water-free formable composition and breakable foams and their uses

    Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10946101

    Surfactant-free water-free foamable compositions, breakable foams and gels and their uses

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is VYNE?

VYNE (VYNE) is a pharma company. headquartered in BRIDGEWATER, NJ, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 7 patents to this profile..

What pipeline programs does VYNE sponsor?

We track 24 ClinicalTrials.gov-linked programs for VYNE, including 5 mg Serlopitant Tablets and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does VYNE company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.